Table 2 Relationship between MADRS total score at baseline and of treatment (ITT) (ANCOVA with baseline score as covariate and treatment as fixed effect)
From: Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies
Treatment | Dependent variable | Fixed factor | Estimate | Degrees of freedom | t value | p value |
|---|---|---|---|---|---|---|
Quetiapine 300 mg/day | MADRS at end of treatment | Intercept | −0.242 | 281 | −0.11 | 0.9119 |
| Â | Â | MADRS at baseline | 0.445 | 281 | 5.86 | <0.0001 |
Quetiapine 600Â mg/day | MADRS at end of treatment | Intercept | 1.127 | 287 | 0.53 | 0.5998 |
| Â | Â | MADRS at baseline | 0.423 | 287 | 5.59 | <0.0001 |
Placebo | MADRS at end of treatment | Intercept | −4.302 | 202 | −1.26 | 0.2086 |
| Â | Â | MADRS at baseline | 0.741 | 202 | 6.23 | <0.0001 |